中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

118 records (took 0.025 seconds)

    진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물
    51.
    发明公开
    진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물 有权
    用于预防和治疗含有GINSENOSIDE RB1和RG3的神经性疼痛的组合物，化合物K或来自PANAX GINSENG的SAPONIN提取物作为有效成分

    公开(公告)号：KR1020120082637A

    公开(公告)日：2012-07-24

    申请号：KR1020110004037

    申请日：2011-01-14

    Applicant: 경희대학교 산학협력단

    Inventor： 윤태영 ,  오태환 ,  김동현 ,  최두철 ,  임은정

    IPC: A61K36/258 ,  A61K31/56 ,  A61P25/00

    CPC classification number: A61K36/258 ,  A23V2200/322

    Abstract: PURPOSE: A composition containing ginsenoside Rb1 and Rg3, compound K, or ginseng-derived saponin extract is provided to suppress pain caused by peripheral nerve injury, central nervous injury, and inflammation. CONSTITUTION: A composition for preventing and treating neuropathic pain contains Panax ginseng-derived saponin extract or saponin isolated from the extract as an active ingredient. The extract is prepared using water, C1-C12 alcohol, or a mixture thereof. A composition contains a compound of chemical formula 1 isolated from the saponin extract as an active ingredient. The compound includes ginsenoside Rb1 of chemical formula 2, ginsenoide Rg3 of chemical formula 3, and compound K of chemical formula 4.

    Abstract translation: 目的：提供含有人参皂苷Rb1和Rg3，化合物K或人参皂甙提取物的组合物，以抑制由周围神经损伤，中枢神经损伤和炎症引起的疼痛。 构成：用于预防和治疗神经性疼痛的组合物含有作为活性成分从提取物中分离的人参来源的皂甙提取物或皂角苷。 提取物是使用水，C1-C12醇或其混合物制备的。 组合物含有从皂甙提取物中分离出的化学式1化合物作为活性成分。 该化合物包括化学式2的人参皂苷Rb1，化学式3的人参皂苷Rg3和化学式4的化合物K.

    항산화 및 피부 세포의 멜라닌 생성을 억제하는 녹용발효물의 제조 방법 및 그에 의한 녹용 발효물
    52.
    发明公开
    항산화 및 피부 세포의 멜라닌 생성을 억제하는 녹용발효물의 제조 방법 및 그에 의한 녹용 발효물 有权
    制备CERVI PARPOR CORNU的发酵产品的方法，用抗氧化和MELANIN形成皮肤细胞的发酵活性和使用其的CERVI PARVUM CORNU的发酵产物

    公开(公告)号：KR1020090075999A

    公开(公告)日：2009-07-13

    申请号：KR1020080001692

    申请日：2008-01-07

    Applicant: 경희대학교 산학협력단

    Inventor： 김동현 ,  김영수 ,  한명주 ,  심규웅

    IPC: A61K35/32 ,  A61K36/899 ,  A61K35/744 ,  A61K8/98

    CPC classification number: A61K35/32 ,  A61K8/981 ,  A61K35/744 ,  A61K36/899

    Abstract: A method for producing a Cervi parvum cornu fermentation is provided to improve the usage to an active ingredient of the Cervi parvum cornu by using lactic acid and suppress the melanogenesis in a cell. A method for producing a Cervi parvum cornu fermentation comprises: a step of dispersing a Cervi parvum cornu with aqueous medium; and a step of fermenting the Cervi parvum cornu by adding rice bran and lactic acid. The rice bran is fermented at 80-120°C for 10-30 minutes. A microorganism having fermentation activity comprises Bacillus licheniformis(KCCM10885P). The lactic acid is Lactobacillus acidophilus(KCTC3164). The lactic acid is Bifidobacterium longum(KCTC 3421).

    Abstract translation: 提供了一种用于生产Cervi parvum cornu发酵的方法，以通过使用乳酸来改善对Cervi parvum cornu的活性成分的使用并抑制细胞中的黑素生成。 一种Cervi parvum cornu发酵方法，其特征在于包括：用水介质分散Cervi parvum cornu的步骤; 以及通过加入米糠和乳酸发酵Cervi parvum cornu的步骤。 米糠在80-120℃下发酵10-30分钟。 具有发酵活性的微生物包括地衣芽孢杆菌（KCCM10885P）。 乳酸是嗜酸乳杆菌（KCTC3164）。 乳酸是长双歧杆菌（KCTC 3421）。

    이리도이드 배당체를 함유하는 항산화제 및 약학적 조성물
    53.
    发明公开
    이리도이드 배당체를 함유하는 항산화제 및 약학적 조성물 失效
    包含红斑狼疮的抗氧化剂和包含其的药物组合物

    公开(公告)号：KR1020070070308A

    公开(公告)日：2007-07-04

    申请号：KR1020050079888

    申请日：2005-08-30

    Applicant: 경희대학교 산학협력단

    Inventor： 김동현 ,  오영준 ,  백남인 ,  정태숙 ,  김민정 ,  김성훈 ,  이효정

    IPC: A61K31/7048 ,  A61K36/748 ,  A61P39/06

    CPC classification number: A61K31/7048 ,  A61K36/748 ,  A61K2236/30 ,  A61K2236/55 ,  Y10S514/824

    Abstract: An anti-oxidant comprising iridoid glycosides and a pharmaceutical composition comprising the same anti-oxidant are provided to inhibit oxidation of LDL(low-density lipoprotein), so that the anti-oxidant is useful for prevention and treatment of cardiovascular diseases caused by LDL oxidation. The anti-oxidant comprises iridoid glycosides represented by the formula(1) and isolated from Oldenlandia diffusa Roxb., wherein R1 and R2 are each independently hydrogen, hydroxyl or optionally hydroxy substituted C1-C5 alkyl; R3 is hydrogen or methyl; R4 is hydrogen, optionally carboxylic acid-substituted C1-C5 alkyl, optionally carboxylic acid-substituted phenyl or optionally carboxylic acid-substituted benzyl; and R5 is Glc or Glc-Ara. The pharmaceutical composition for preventing or treating cardiovascular diseases comprises the iridoid glycosides represented by the formula(1), wherein the cardiovascular diseases include hyperlipidemia, coronary heart disease, atherosclerosis, atherosclerosis and myocardial infarction. The iridoid glycosides represented by the formula(1) is produced by (a) extracting Oldenlandia diffusa Roxb. with C1-C5 organic solvent, (b) fractionating the extract of Oldenlandia diffusa Roxb. with water, ethanol and n-butanol sequentially, and (c) subjecting the n-butanol fraction to chromatography.

    Abstract translation: 提供包含环烯醚萜苷的抗氧化剂和包含相同抗氧化剂的药物组合物以抑制LDL（低密度脂蛋白）的氧化，使得抗氧化剂可用于预防和治疗由LDL氧化引起的心血管疾病 。 抗氧化剂包括由式（1）表示的并且分离自阿尔德兰德氏菌属Roxb的环烯醚萜苷，其中R 1和R 2各自独立地为氢，羟基或任选的羟基取代的C 1 -C 5烷基; R3是氢或甲基; R 4是氢，任选地羧酸取代的C 1 -C 5烷基，任选地羧酸取代的苯基或任选的羧酸取代的苄基; R5是Glc或Glc-Ara。 用于预防或治疗心血管疾病的药物组合物包括由式（1）表示的环烯醚萜苷，其中心血管疾病包括高脂血症，冠心病，动脉粥样硬化，动脉粥样硬化和心肌梗死。 由式（1）表示的环烯醚萜糖苷通过（a）提取古老的en usa usa is is制成。 用C1-C5有机溶剂，（b）分离Oldenlandia diffusa Roxb的提取物。 依次用水，乙醇和正丁醇，和（c）使正丁醇级分进行色谱。

    파킨슨병을 진단하기 위한 정보제공방법
    59.
    发明授权
    파킨슨병을 진단하기 위한 정보제공방법 有权

    公开(公告)号：KR101860566B1

    公开(公告)日：2018-05-23

    申请号：KR1020160165136

    申请日：2016-12-06

    Applicant: 경희대학교 산학협력단

    Inventor： 오명숙 ,  김동현 ,  최진규

    IPC: G01N33/68 ,  G01N33/569 ,  A01K67/027

    CPC classification number: A01K67/027 ,  A01K2207/20 ,  A01K2207/25 ,  A01K2267/0318 ,  G01N33/56916 ,  G01N33/6896 ,  G01N2333/265 ,  G01N2400/50

    Abstract: 본발명은피검체의생물학적시료로부터프로테우스미라빌리스() 균주, 프로테우스미라빌리스균주에의해생성된대사산물및 알파-시누클레인(α-synuclein)으로이루어진군으로부터선택된어느하나의대상의양을측정하여파킨슨병을진단하기위한정보제공방법, 프로테우스미라빌리스균주를유효성분으로포함하는파킨슨병동물모델제조용조성물, 인간을제외한동물에프로테우스미라빌리스균주를투여하는단계를포함하는파킨슨병동물모델제조방법및 상기파킨슨병동물모델에파킨슨병치료제후보약물을투여하는단계및 파킨슨병증상의완화정도를관찰하여후보약물의파킨슨병치료효과를판단하는단계를포함하는파킨슨병치료제의스크리닝방법에관한것이다.

Patent Agency Ranking